Weil Advised Sanofi in its $1.45 Billion Acquisition of Kymab, Ltd.
Weil advised Sanofi in its $1.45 billion acquisition of Kymab, Ltd., a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The transaction resulted in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. The transaction closed on April 09, 2021.
The Weil team that advised Sanofi was led by Mergers & Acquisitions partners Michael J. Aiello and Michael Francies and included Mergers & Acquisitions associates Jack Gray, Iliana Ivanova, Michael Grant, Tom Tsatsis and Rhys Williams. The team also included Banking & Finance partners Reena Gogna and Morgan Bale; Banking & Finance counsel Ben Burton; Tax partners Jenny Doak and Graham Magill; Tax associate Akash Mehta; Executive Compensation & Benefits Head Paul Wessel; Technology & IP Transactions Head Michael Epstein; Technology & IP Transactions/Privacy partner Barry Fishley; Technology & IP Transactions/Privacy counsel Briony Pollard; Technology & IP Transactions/Privacy associates Caleb Small and Madeline Koo; Antitrust partner John Scribner; Antitrust counsel Michael Naughton; and Antitrust associate Vivian Wang.
More from the Weil Tax Blog
Copyright © 2024 Weil, Gotshal & Manges LLP, All Rights Reserved. The contents of this website may contain attorney advertising under the laws of various states. Prior results do not guarantee a similar outcome. Weil, Gotshal & Manges LLP is headquartered in New York and has office locations in Boston, Brussels, Dallas, Frankfurt, Hong Kong, Houston, London, Miami, Munich, New York, Paris, Shanghai, Silicon Valley and Washington, D.C.